Case series of pectoral hematoma associated with enoxaparin use in elderly patients

Mehmet Sami Islamoglu (✉ mislamoglu@biruni.edu.tr)

Biruni University Faculty of Medicine: Biruni Universitesi Tip Fakultesi

Mahir Cengiz

Biruni University Faculty of Medicine: Biruni Universitesi Tip Fakultesi

Betul Borku Uysal

Biruni University Faculty of Medicine: Biruni Universitesi Tip Fakultesi

Suna Koc

Biruni University Faculty of Medicine: Biruni Universitesi Tip Fakultesi

Omer Faruk Unal

Biruni University Faculty of Medicine: Biruni Universitesi Tip Fakultesi

Serap Yavuzer

Biruni University Faculty of Medicine: Biruni Universitesi Tip Fakultesi

Research Article

Keywords: enoxaparin, pectoral haematoma, low molecular heparine, elderly, renal failure

Posted Date: July 28th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-742598/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Venous thromboembolism is among the common and preventable cardiovascular syndromes. The risk of thromboembolism is increased in elderly and patients with renal failure, and the risk of bleeding due to the use of anticoagulants also increases. Pectoral hematoma due to enoxaparin are presented rarely unlike other bleeding localisation. In this article, 3 cases of pectoral hematoma due to enoxaparin are presented in the light of the literature, especially in this period when the use of anticoagulants is increasing.

Case presentation

Two of the 3 cases over the age of 65 were in the intensive care unit, and the other patient received low molecular weight heparin therapy during outpatient follow-up. In these cases enoxaparin use for profilactic and treatment dosages. After anticoagulant using pectoral hematoma was diagnosed by ultrasonography and computed tomography of the thorax in patients. One patient was died from sepsis but in two of other with the discontinuation of the treatment, the size of the hematoma decreased and the treatment change was sufficient.

Conclusion

Low molecular weight heparins are used in the treatment and prevention of thromboembolism. In elderly and patients with renal failure, care should be taken in terms of pectoral bleeding and other bleeding.

Background

Venous thromboembolism is seen commonly and preventable disease among cardiovascular syndromes. Embolism is more common in elderly patients and patients with renal failure, with a mortal course and the risk of bleeding is higher (1). Enoxaparin, a member of the Low Molecular Weight Heparin (LMWH) group, is used in the prevention of clot formation such as deep vein thrombosis, pulmonary embolism and the treatment of myocardial infarction (2). Compared to unfractionated heparin, the risk of bleeding, development of osteoporosis and heparin-induced thrombocytopenia are seen lower. Additionally, it is usually preferred firstly instead of heparin due good bioavailability, easy usage and long half-life. Intramuscular bleeding is a serious and mortal complication of anticoagulant treatments (3). Although anterior chest wall bleeding is less than pneumothorax and hemothorax, it occurs commonly in trauma. Spontaneous anterior chest wall bleeding has been reported rarely associated with anticoagulant therapy (4). In this article due to its rarity, three cases of pectoral hematoma are presented in the light of the literature in the period of anticoagulant use is increasing, especially in co-morbid patients

Case-1

87-year-old male patient with a known history of hypertension and cerebrovascular disease was admitted to the emergency service with dyspnea and general condition disorder. The patient was taken to the intensive care unit with diagnoses of pneumonia and sepsis. LMWH treatment enoxsarine was started as a renal treatment dosage due to having past cerebrovascular event. In the patient who received enoxsarine for 1 month, swelling and pain in the anterior thorax were detected and hematomas of 3 santimeter (cm) on the right and 2,5 cm on the left were detected in the bilateral pectoral region by thorax computed tomography (CT) (**Figure 1a**). The four erythrocyte suspension transfusions were given for anemia. LMWH treatment was discontinued. After thrombocytopenia were given four fresh frozen plasma. Regression was observed after seven day in the control thorax CT of the patient (**Figure 1b**). Pneumonia and sepsis progressed. The patient died from septic shock after ten day

Case-2

A 92-year-old female patient with Alzheimer's disease, who did not have oral intake and was fed with a nasogastric tube, was admitted to the emergency department with fever and general condition disorder. The patient was taken to the intensive care unit with starting noninvasive mechanical ventilation due to urinary infection. In the patient with high thrombosis risk, enoxoparine treatment was initiated at a prophylaxis dose. On the 15th day of treatment, 5,5x3 cm hematoma was detected with ultrasonography when swelling was seen in the anterior chest wall. The patient, whose LMWH treatment was discontinued, was followed-up and discharged after ten days.

Case-3

67-year-old male patient was admitted to the internal medicine outpatient clinic with weakness, shortness of breath, and chest pain. Filling defect consistent with pulmonary embolism was detected. The patient was started on enoxaparin therapy at a dosage of 1 miligram/kilogram (2x8000 IU). Higher dose anticoagulant treatment was initiated because the patient's body mass index was over 30. On the seven day of enoxaparin treatment, swelling was detected in the left chest, and a dense content compatible with hematoma with a size of 55x60 mm was detected in the muscle planes of the left pectoral region. Bemiparin treatment, one of the anti factor Xa inhibitors, was started by discontinuing enoxaparin. With the regression of the hematoma, it was continued with oral anticoagulant therapy.

Discussion

A rare complication of LMAH therapy, pectoral hematoma was detected in our three elderly patients with different diagnoses. Laboratory findings and enoxaparine doses were shown in the **Table 1**. Hematomas were resolved by the cessation of treatment and change of anticoagulant therapy.

Enoxaparin inhibits Factor Xa like heparine and is effective at low doses by binding less to plasma proteins (2). Anti-factor Xa measurement is recommended for dose adjustment in special groups of patients such as pregnancy, renal insufficiency and obesity (5). It has been shown that LMWH treatment is not non-inferior to unfractionated heparin in pulmonary embolism and deep vein thrombosis, and it is

used safely instead of heparin in many areas (5). Hematuria due to enoxaparin (6), gastrointestinal bleeding (7) and retroperitoneal bleeding (8) have been reported more frequently in the literature. As a case report pectoral hematoma with enoxaparin was reported by Ozpolat et al. and bleeding in the anterior chest wall was reported by Subedi et al. (9–10).

Conclusion

When venous thromboembolism is not treated, it causes high mortality and morbidity. Low molecular weight heparin therapies, which are commonly used in treatment, have fewer side effects than unfractionated heparin. Despite its advantages, because of the risk of bleeding, enoxaparine should be used with caution and at appropriate doses in elderly and patients with renal insufficiency.

Abbreviations

LMWH: Low Molecular Weight Heparin

CT: Computed Tomography

Declarations

Ethics approval and consent to participate

In Turkey, a case report does not require ethics approval.

Consent for publication

Written informed consent for publication of identifying images and other personal or clinical details was obtained from the patient

Availability of data and material

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study

Competing interests

The authors declare that they have no competing interests.

Funding

None

Authors' contributions

Conceptualization: Mehmet Sami Islamoglu, Mahir Cengiz **Formal analysis and investigation:** Betul Borku Uysal, Omer Faruk Unal,. **Writing - original draft preparation:** Suna Koc, Serap Yavuzer. All authors read and approved the final manuscript.

Acknowledgements

No

References

1. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ,et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e152S-e184S.
2. . Hao C, Sun M, Wang H, Zhang L, Wang W. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21–39.
3. Dohan A, Darnige L, Sapoval M, Pellerin O. Spontaneous soft tissue hematomas. Diagn Interv Imaging. 2015 Jul-Aug;96(7–8):789–96. doi: 10.1016/j.diii.2015.03.014. Epub 2015 Jun 9. PMID: 26066549.
4. Sato N, Sekiguchi H, Hirose Y, Yoshida S. Delayed chest wall hematoma caused by progressive displacement of rib fractures after blunt trauma. Trauma Case Rep. 2016 Jun 14;4:1–4. doi: 10.1016/j.tcr.2016.05.001. PMID: 29942843; PMCID: PMC6011857.
5. Shaikh SA, Regal RE. Dosing of Enoxaparin in Renal Impairment. P T. 2017 Apr;42(4):245–9. PMID: 28381917; PMCID: PMC5358682.
6. Schuster GA, Lewis GA. Clinical significance of hematuria in patients on anticoagulant therapy. J Urol. 1987;137(5):923–5.
7. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc. 2003;58(3):369–73.
8. Triscott J, Mercer S, Tian PG, Dobbs B. Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease. BMJ Case Rep. 2015 Oct;5:2015:bcr2015211699.
9. Ozpolat B, Yazkan R, Aksoy M, Doğan S. Spontaneous pectoral hematoma secondary to enoxaparin for the treatment of deep venous thrombosis in an elderly man. Anadolu Kardiyol Derg. 2008 Dec 25;8(6):E40.
10. Subedi P, Syed MP, Shah T, Siddiqui AD. Spontaneous large anterior chest wall haematoma causing haemorrhagic shock during enoxaparin therapy. BMJ Case Rep. 2020 Jun 2;13(6):e235887. doi: 10.1136/bcr-2020-235887. PMID: 32487524; PMCID: PMC7269540.

Tables

Table-1. Laboratory findings and enoxaparine dosages in cases of pectoral haematoma

	Case-1	Case-2	Case-3
Leukocyte (K/uL)	11.920	7200	9000
Haemoglobin (g/dl)	7.0	8,0	13,6
Platelet (K/uL)	72.000	241.000	237.000
Protrombin Time (second)	12,7	15,6	12
Inr	1,25	1.56	1,0
Aptt (second)	62,8	29,6	36
Creatinin (mg/dl)	1,51	1,46	0,67
eGfr(mililiter/minute)	43,9	33,5	118
Enoxaparin Dosage	6000Anti-Xa IU/0,6ml 1x1	4000 AntiXa IU /0,4ml 1x1	4000 AntiXa IU/0,4 ml 2x2
Duration of enoxaparine use when pectoral haemotoma occurs	30 th day	15 th day	7 th day

Figures

Figure 1

(a) Bilateral pectoral haematoma images in computed thorax tomography (b) Regression of pectoral haematoma after enoxaparin discontinued